Baird Medical Investment Holdings Limited (BDMD)
Nasdaq · Healthcare · Medical Devices
$0.7429−1.08%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $23.9M
- Forward P/E
- 5.3
- 52-week range
- $0.661 – $3.70
- 52-week change
- −56.84%
- EPS (trailing)
- −$0.55
Fiscal year to Dec 2025
- Revenue
- $22.5M (−39.15%)
- Net income
- −$27.3M
- Operating margin
- −113.7%
- Diluted EPS
- −$0.98
- Free cash flow
- −$1.4M
From the company’s annual report on SEC EDGAR.
About Baird Medical Investment Holdings Limited
Baird Medical Investment Holdings Limited, together with its subsidiaries, engages in research, development, manufacturing, and sales of microwave ablation and other medical devices in the People's Republic of China. The company offers microwave ablation apparatus and needles; and long and fine microwave ablation needles for the treatment of benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer, and breast lumps, and uterine fibroids, as well as soft tissue ablation. It sells its products through third-party distributors. It has a strategic cooperation agreement with Tianjin Yuanshan Medical Technology Co., Ltd. to focus on global development and commercialization of next-generation IRE technologies. Baird Medical Investment Holdings Limited was founded in 2012 and is based in Guangzhou, China.
Headquarters: Guangzhou, China · 146 employees · bairdmed.com